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Background. The role of circulating levels of total homocysteine tHcy in the development of coronary heart disease (CHD) is
still under debate. One reason for conflicting results between previous studies on homocysteine and heart diseases could be
consequence of different interactions between homocysteine and genes in different study populations. Many genetic factors
play a role in folate-homocysteine metabolism, like functional polymorphism (Val108Met) in the Catechol-O-methyltransferase
(COMT) gene. Methodology and Findings. Our aim was to examine the role of COMT Val158Met polymorphism and
interaction of this polymorphism with serum tHcy and folate concentration on the risk of acute coronary and events in middle-
aged men from eastern Finland. A population-based prospective cohort of 792 men aged 46–64 years was examined as part of
the Kuopio Ischaemic Heart Disease Risk Factor Study. During an average follow-up of 9.3 years, there were 69 acute coronary
events in men with no previous history of CHD. When comparing the COMT low activity genotype with the others, we found an
age and examination year adjusted hazard rate ratio (HRR) of 1.73 (95% confidence interval (CI), 1.07–2.79), and an age,
examination year, serum LDL and HDL cholesterol, and triglyceride concentration, systolic blood pressure and smoking
adjusted HRR of 1.77 (95% CI, 1.05–2.77). Although serum tHcy concentration was not statistically significantly associated with
acute coronary events (HRR for the highest third versus others 1.52, 95% CI, 0.93–2.49), subjects with both high serum tHcy and
the COMT low activity genotype had an additionally increased adjusted risk of HRR 2.94 (95% CI 1.50–5.76) as compared with
other men. Conclusions. This prospective cohort study suggests that the functional COMT Val158Met polymorphism is
associated with increased risk of acute coronary events and it may interact with high serum tHcy levels.
Citation: Voutilainen S, Tuomainen T-P, Korhonen M, Mursu J, Virtanen JK, et al (2007) Functional COMT Val158Met Polymorphism, Risk of Acute
Coronary Events and Serum Homocysteine: The Kuopio Ischaemic Heart Disease Risk Factor Study. PLoS ONE 2(1): e181. doi:10.1371/
journal.pone.0000181
INTRODUCTION
Nutrition has a significant role in the prevention of many chronic
diseases such as cardiovascular disease (CVD), cancers and
degenerative brain diseases. Major risk and protective factors in
the diet are now known, however, new candidates in both
categories are still being revealed. Especially, the associations
between nutrition and genes in disease risk have not been studied
extensively.
During the last years, elevated plasma/serum total homocys-
teine (tHcy) has been one of the most intensely studied risk factors
for CVD [1,2]. We have shown in the Kuopio Ischaemic Heart
Disease Risk Factor (KIHD) Study that a high serum concentra-
tion and dietary intake of folate are associated with a significantly
lower risk of acute coronary events [3–5], while an elevated
plasma tHcy concentration was not significantly associated with an
increased risk [5–6].
There are some well-known genetic factors that have a role in
the folate-Hcy metabolism, like methylenetetrahydrofolate re-
ductase (MTHFR) and cystathionine ß-synthase (CBS) [7,8].
There are also some less studied genetic factors in that metabolism,
which could have a role in Hcy-CVD association. Catechol-O-
methyltransferase (COMT) is an enzyme that catalyzes the O-
methylation of various compounds, like catechol estrogens and
dietary polyphenols, using S-adenosylmethionine (SAM) as the
methyl donor and has also a role in dopamine inactivation. A
common functional polymorphism (Val108Met) in the COMT
gene is associated with a three- to four-fold variation in enzyme
activity [9,10]. The low activity genotype (Met158Met) has been
associated with heavy alcohol use [11] and some other psychiatric
disorders, such as bipolar disorder and schizophrenia [12].
A unifying hypothesis that hyperhomocysteinemia may exert its
pathogenic effects largely through metabolic accumulation of
SAH, a potent non-competitive inhibitor of COMT-mediated
methylation metabolism of various catechol substrates was recently
proposed [10]. Therefore we wanted to test the hypothesis that the
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the coronary event risk, and that the effect is further strengthened
by elevated tHcy.
MATERIALS AND METHODS
Study design and population
The Kuopio Ischaemic Heart Disease Risk Factor (KIHD) Study
is an ongoing prospective population-based cohort study designed
to investigate risk factors for CVD, atherosclerosis and related
outcomes in middle-aged men from eastern Finland [13],
a population with one of the highest recorded rates of coronary
heart disease (CHD). A total of 2682 participants (82.9% of those
eligible), aged 42, 48, 54, or 60 years, were enrolled in the study
between 1984 and 1989. The baseline examinations for the
present prospective cohort study were carried out during 1991 to
1993. Out of a total of 1229 men eligible for the study, 52 had
died, or suffered severe illness, or had migrated from the region,
and 139 could not be contacted or refused to participate. Of the
remaining 1038 men, data on serum folate and tHcy concentra-
tion and COMT genotype were available for 1012 men. As
previous disease may affect circulating levels of tHcy and dietary
intake of nutrients, men with prevalent CHD (n=220) were
excluded from the main analyses of this study. All participants
signed a written informed consent. The Research Ethics
Committee of the University of Kuopio has approved the KIHD
study protocol.
Measurements
The subjects came to give venous blood samples between 8 and 10
in the morning. They were instructed to abstain from ingesting
alcohol for three days and from smoking and eating for 12 hours.
After the subject had rested in the supine position for 30 minutes,
venous blood samples were collected into vacuum tubes (Venoject;
Terumo, Leuven, Belgium). No tourniquet was used. Blood for
folate and cholesterol determination and for lipoprotein separation
was drawn into serum tubes.
COMT polymorphism is generated by the presence of guanine
or adenine at nucleotide 475 encoding a valine (Val) or methionine
(Met) at codon 158 [14]. The polymorphism results in three
different genotypes: homozygous for the low activity allele (Met/
Met), homozygous for the high activity allele (Val/Val), and
heterozygous (Met/Val). DNA was extracted from 10 ml of
venous EDTA blood using standard salting-out or phenol-
chloroform assays. COMT genotypes were determined by re-
striction fragment length polymorphism (RFLP) analysis from the
DNA by an investigator unaware of the phenotype. A 179 base-
pair polymerase chain reaction product was generated using the
forward 59-CTG CTG GAG CTG GGG GCC GAC-39 and
reverse 59-AGG TCT TCA GGA ATG C-39 primers. The
polymerase chain reaction product was treated with HSP 92 II
restriction endonuclease. The diagnostic bands were 179 (Val) and
139 (Met).
The serum tHcy concentration was analyzed by HPLC in 2001
at the National Public Health Institute, Helsinki, Finland [15].
The coefficients of variation (CV) between batches (n=30) for two
pooled serum samples were 4.3% and 5.4%.
Serum folate and vitamin B12 concentrations were measured by
radioimmunoassay (Quantaphase II, Bio-Rad, Hercules, Califor-
nia, USA). These measurements were carried out in 1998 from
serum samples collected during 1991–3 and kept frozen at 280uC.
The between-batch CV of quality control serums (Lyphochek
Immunoassay Plus Control levels 1, 2, 3, Bio Rad Laboratories,
ECS Division, Anaheim, California, USA) for folate levels of 5.5,
13.4 and 23.6 nmol/L were 6.4, 6.7 and 6.7%, respectively
(n=16).
Serum lipoproteins were separated from fresh serum samples by
combined ultracentrifugation and precipitation [16]. Serum total,
LDL and HDL cholesterol (Kone Instruments, Espoo, Finland)
and triglyceride (Boehringer Mannheim, Mannheim, Germany)
concentrations were determined enzymatically with an autoana-
lyzer (Kone Specific, Kone Instruments, Finland).
Two trained nurses measured resting blood pressure with
a random-zero mercury sphygmomanometer (Hawksley, United
Kingdom). The measuring protocol included, after supine rest of
five minutes, three measurements in the supine, one in the
standing and two in the sitting position at five minute intervals.
The mean of all six measurements was used as the systolic and
diastolic blood pressure. Body mass index (BMI) was computed as
the ratio of weight to the square of height. Assessment of smoking
and ischemic disease in the family was carried out as described
previously [17].
Ascertainment of follow-up events
The province of Kuopio participated in the multinational
MONICA (MONItoring of Trends and Determinants of Cardio-
vascular Disease) project [18], in which detailed diagnostic
information of all heart attacks that occurred by December 1992
was collected prospectively. Diagnostic classification was made by
the FINMONICA coronary registry group [18]. Data on acute
coronary events between January 1993 and December 2002 were
obtained by computer linkage to the national hospital discharge
register and classified using identical diagnostic criteria, based on
symptoms, cardiac enzymes and electrocardiographic findings as
documented previously [18]. The average follow-up time was 9.3
years. If multiple non-fatal events occurred during the follow-up,
the first event for each subject was considered as end point for the
analyses. According to the diagnostic classification of the events
there were 43 definite and 17 possible acute myocardial infarctions
(AMI) and 9 typical prolonged chest pain episodes in men free of
prior CHD at study baseline, a total of 69 events without history.
Statistics
The data are expressed as means6SD. Means were compared by
analysis of variance (ANOVA). The subjects were classified into
thirds according to their serum folate and tHcy concentration and
those in the highest third were compared with those in the two
lower thirds. The relationship of serum folate and tHcy with the
risk of acute coronary events in COMT genotypes was analyzed
using the Cox proportional hazards models. We used age,
examination year, serum HDL and LDL cholesterol and
triglycerides, mean systolic blood pressure and smoking as
covariates in the main analysis.
Interactions between genotype and serum tHcy and genotype
and folate on the risk of acute coronary events were tested on both
the multiplicative and additive scales. First, the ]multiplicative
interaction between genotype and serum tHcy was assessed by the
use of a product term that was serum tHcy $11.3 mmol/L *
COMT low activity (Met158Met) genotype. Where the estimated
b coefficient for the product term does not equal zero or the
respective hazard rate ratio (HRR) does not equal one,
a multiplicative interaction exists. An additive interaction was
assessed using the estimated relative excess risk for interaction
(RERI) [19]. Briefly, RERI=HRR112HRR102HRR01+1, where
HRR11 refers to the hazard rate ratio of acute coronary event
associated with both genotype and serum tHcy, HRR10 and
HRR01 are hazard rate ratios of acute coronary event associated
Homocysteine, COMT and AMI
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does not equal zero suggests an additive interaction. The
interactions between genotype and folate were assessed in the
same way. The product term for serum folate was serum folate
#8.3 nmol/L * COMT Met158Met genotype.
The confidence intervals (CI) were estimated on the basis of the
assumption of asymptotic normality of the estimates. All tests of
significance were two-sided. P-values ,0.05 were considered
significant. Data were analyzed using SPSS 11.0 for Windows
(SPSS Inc., Chicago, IL, USA).
RESULTS
Characteristics
At the beginning of follow-up, the mean age of the study men was
55.4 years. During an average follow-up time of 9.3 years, 69 men
with no previous CHD at baseline suffered an acute coronary
event. Those subjects who suffered an acute coronary event had
higher systolic blood pressure, serum total and LDL cholesterol
and triglycerides and a higher prevalence of ischemic heart disease
in the family, and also had lower serum folate concentration than
the other subjects (Table 1).
The distribution of the COMT genotypes was consistent with the
Hardy-Weinberg equilibrium. The frequency of the Val/Val,
Val/Met and Met/Met genotypes in healthy controls was 22.0,
50.3 and 27.7%, respectively (p=0.78). In the whole study
population the prevalence of heterozygosity and homozygosity of
COMT Met158 were 49.4% and 28.9%, respectively. Table 2
exhibits baseline characteristics of the study subjects according to
the COMT genotypes. There was no significant difference in by
age, serum HDL, LDL or triglycerides, systolic blood pressure or
smoking status in different COMT genotypes. There was also no
statistically significant association between COMT genotypes with
either serum tHcy or folate levels.
Table 1. Baseline characteristics of the study subjects
*
..................................................................................................................................................
Characteristic All subjects (n=792)
Subjects who developed an
acute coronary event (n=69)
Other subjects
(n=724)
p-value for difference
in means
Serum tHcy, mmol/L 10.863.4 11.063.4 10.863.3 0.622
Serum folate, nmol/L 10.3563.93 9.3463.93 10.4563.92 0.025
Mean age, y 55.466.6 56.366.6 55.366.6 0.197
BMI, kg/m
2 27.563.6 28.263.3 27.463.6 0.101
Systolic blood pressure, mmHg 135617 141615 135617 0.003
Total cholesterol, mmol/L 5.5060.90 5.7960.83 5.4760.90 0.005
LDL cholesterol, mmol/L 3.9160.81 4.1460.72 3.8960.81 0.012
HDL cholesterol, mmol/L 1.1160.29 1.0860.30 1.1260.28 0.285
Triglycerides, mmol/L 1.5761.03 1.8961.42 1.5460.98 0.007
Current Smokers, % 26.8 31.8 26.3 0.280
IHD in family, % 50.3 66.7 48.7 0.004
Abbreviations: BMI=body mass index; HDL=high density lipoprotein; IHD=ischemic heart disease; LDL=low density lipoprotein; tHcy=total homocysteine
concentration.
*Data are expressed as the mean6SD unless otherwise indicated.
doi:10.1371/journal.pone.0000181.t001
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Table 2. Characteristics of the study subjects according to the catechol-o-methyltransferase (COMT) genotypes
*
..................................................................................................................................................
Characteristic COMT
Val158Val (n=172) COMT
Val158Met (n=391) COMT
Met158Met (n=229) p-value
Serum tHcy, mmol/L 11.064.4 10.763.2 10.962.6 0.521
Serum folate, nmol/L 10.364.2 10.463.8 10.364.0 0.927
Age, y 55.466.6 54.966.4 56.167.0 0.086
BMI, kg/m
2 27.463.5 27.363.5 27.963.7 0.147
Systolic blood pressure, mmHg 134615 135617 136617 0.397
Total cholesterol, mmol/L 5.6360.90 5.4360.93 5.5260.84 0.056
LDL cholesterol, mmol/L 4.0260.80 3.8560.83 3.9360.76 0.060
HDL cholesterol, mmol/L 1.1260.29 1.0960.26 1.1460.33 0.061
Triglycerides, mmol/L 1.5560.87 1.5760.98 1.5861.23 0.944
Current smokers, % 26.9 26.6 27.1 0.991
IHD in family, % 53.5 47.3 52.8 0.262
Subjects who developed an acute coronary event, % 8.0 7.0 13.0 0.041
Abbreviations: BMI=body mass index; HDL=high density lipoprotein; IHD=ischemic heart disease; LDL=low density lipoprotein; tHcy=total homocysteine
concentration.
*Data are expressed as the mean6SD unless otherwise indicated.
doi:10.1371/journal.pone.0000181.t002
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acute coronary event
Serum tHcy concentration was not significantly associated with
the risk of acute coronary event. Men with high serum tHcy
concentrations (highest third, $11.3 mmol/L) had a 1.41-fold
(95% CI, 0.87–2.29, p=0.164) risk of acute coronary events after
adjusting for age and examination year and 1.52-fold (95% CI,
0.93–2.49, p=0.092) risk after adjusting for age, examination year,
serum HDL and LDL cholesterol and triglyceride concentration,
systolic blood pressure and smoking as compared with men with
lower serum tHcy. Additional adjustment with serum folate
decreased this risk to 1.32 (95% CI, 0.80–2.18, p=0.283).
Subdividing serum tHcy into quarters or adjustment for other
dietary or lifestyle factors did not reveal significant associations
between tHcy and coronary events.
A low serum folate concentration (lowest third, #8.3 nmol/L)
was associated with a significantly higher risk of acute coronary
events. In the Cox model adjusted for age and examination
years, and serum LDL- and HDL- cholesterol and triglycerides,
systolic blood pressure and smoking, the HRR for those in the
lowest serum folate third was 1.72 (95% CI 1.06–2.79,
p=0.028) as compared with others. Adjustment for other
nutritional or lifestyle factors did not substantially attenuate
this association.
COMT low activity Met158Met genotype and the
risk of acute coronary event
The COMT low activity genotype was associated with a higher risk
of acute coronary events. In the comparison of the men with the
COMT Met158Met genotype with the others, we found age and
examination year adjusted HRR of 1.73 (1.07–2.79, p=0.025),
and age, examination year, serum HDL and LDL cholesterol, and
triglyceride concentration, systolic blood pressure and smoking
adjusted HRR of 1.77 (1.05–2.77, p=0.030).
Interactions between serum homocysteine and
folate, COMT Met158Met genotype and acute
coronary event risk
Table 3 presents the adjusted HRR’s and 95% CI’s of incident
coronary events associated with gene-tHcy and gene-folate
interactions. HRR’s for coronary events were 1 for individuals
with ‘non-risk’ genotype: subjects with COMT Val/Met genotype
and either low serum tHcy (lowest third) for homocysteine-gene
analyses or high serum folate (highest third) for folate – gene
interaction analyses. HRR for interaction and RERI with 95%
CI’s are also displayed.
When comparing men with both high plasma tHcy (highest
third) and COMT Met158Met genotype with the men with lower
serum tHcy and COMT Met158Val or Val158Val genotype, we
found age and examination year adjusted HRR of 2.60 of acute
coronary event (95% CI 1.35–5.03, p=0.004) (Table 3). After
adjusting for age, examination years, serum HDL and LDL
cholesterol and triglycerides, systolic blood pressure and smoking
the HRR was 2.94 (95% CI 1.50–5.76, p=0.002). There was no
significant association between high serum tHcy and acute
coronary events in men with other COMT genotypes. In Table 3,
however, the results suggest no statistically significant multiplica-
tive nor additive interaction between COMT genotype and serum
tHcy (p-values .0.05). Figure 1 presents Kaplan-Meier survival
curves for 1) study subjects with lower serum tHcy (,11.28 mmol/
L) and no COMT Met158Met genotype, 2) study subjects with
higher serum tHcy ($11.28 mmol/L) and no COMT Met158Met
genotype, 3) study subjects with low serum tHcy and COMT
Met158Met genotype, and 4) for the study subjects with higher
serum tHcy and COMT Met158Met high-risk genotype.
In order to study the interaction between serum folate levels and
COMT genotypes, we conducted similar analyses with serum
folate. Men with both low serum folate and COMT Met158Met
genotype had a adjusted HRR of 2.80 (95% CI 1.33–3.90,
p=0.007) when compared with men having high serum folate and
Table 3. Adjusted HRR and 95% CI of Incident Acute Coronary Events Associated with the COMT Genotype*, Plasma tHcy and
Serum Folate and Gene-Homocysteine and Gene-Folate Interactions
..................................................................................................................................................
Homocysteine, exposure definition
High tHcy, COMT Val158Met
or Val158Val
Low tHcy with COMT
Met158Met
High tHcy with COMT
Met158Met Multiplicative interaction
Additive
interaction
HRR (95% CI) p-value HRR (95% CI) p-value HRR (95% CI) p-value HRRi (95% CI) p-value RERI (95% CI)
Model 1{ 1.15 (0.60–2.20) 0.68 1.42 (0.75–2.68) 0.28 2.60 (1.35–5.03) 0.004 1.60 (0.60–4.25) 0.35 1.03 (20.30–2.36)
Model 2{ 1.20 (0.62–2.30) 0.59 1.34 (0.70–2.56) 0.37 2.94 (1.50–5.76) 0.002 1.84 (0.68–4.95) 0.23 1.40 (20.43–3.23)
Folate, exposure definition
Low fol with COMT
Val158Met or Val158Val
High fol with COMT
Met158Met
Low fol with COMT
Met158Met
Multiplicative interaction Additive
interaction
HRR (95% CI) p-value HRR (95% CI) p-value HRR (95% CI) p-value HRRi (95% CI) p-value RERI (95% CI)
Model 1{ 1.95 (1.05–3.63) 0.036 2.11 (1.11–4.01) 0.022 2.67 (1.28–5.59) 0.009 0.65 (0.25–1.73) 0.39 20.39 (22.60–1.83)
Model 2{ 2.05 (1.10–3.85) 0.025 2.07 (1.09–3.94) 0.027 2.80 (1.33–5.90) 0.007 0.66 (0.25–1.76) 0.41 20.32 (22.82–2.18)
Abbreviations: CI, confidence interval; COMT, catehol-O-methyltransferase; fol, serum folate concentration; HRR, hazard rate ratio; HRRi, hazard rate ratio for
a multiplicative interaction; RERI, relative excess risk for interaction; tHcy, serum total homocysteine concentration.
*COMT low activity Met158Met is ‘at-risk’ genotype for this study. The comparison group for the HRRs in the first three columns of the table is the same, i.e. subjects with
lower plasma tHcy (,11.3 mmol/L) with COMT Met158Val or Val158Val genotype.
{Model 1 is adjusted for age and examination years.
{Model 2 is adjusted for age, examination years, serum HDL and LDL cholesterol and triglycerides, systolic blood pressure and smoking
doi:10.1371/journal.pone.0000181.t003
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PLoS ONE | www.plosone.org 4 January 2007 | Issue 1 | e181other COMT genotypes (Table 3). Nevertheless, the interaction
between COMT genotype and serum folate was not statistically
significant either on the multiplicative or additive scale (p-values
.0.05).
DISCUSSION
The main finding of this study is that the common functional
Met158Met polymorphism of the COMT gene is an independent
risk factor for acute coronary events in Finnish men and it may
also interact with serum tHcy to increase the risk of coronary
events further. Recently Eriksson and colleagues we have shown
opposite results. In their prospectively followed hypertensive
cohort of 174 patients and 348 controls the low activity genotype
reduces the risk of myocardial infarction [20]. They also noticed
that men who were homozygous for the low activity allele of
COMT had increased serum levels of estradiol, and concluded
that the altered estrogen status could be involved in this effect. In
that study 74% of study subjects were men and interaction
between COMT genotype and homocysteine were not studied.
It is biologically plausible that the COMT variant directly
modifies the association between high serum tHcy levels and risk
of CHD because of prior evidence suggests that COMT is one of
the key enzymes in the methionine-homocysteine metabolism
[10]. An alternative explanation for our findings is that other genes
on chromosome 22 with functional mutations are in linkage
disequilibrium with the COMT variant evaluated herein. Homo-
cysteine is a sulphur-containing amino acid which is converted to
SAM, formed only from the dietary essential amino acid
methionine. Via the action of SAM adenosyltransferase, methio-
nine is converted to SAM, which is the major biological methyl
donor required for numerous cellular processes, including the
formation of creatine and methylation of phospholipids. These
reactions are catalyzed by various methyltransferases, such as
COMT, which demethylates s-adenosylmethionine to SAH, the
immediate precursor of homocysteine. Recently a unifying
hypothesis that hyperhomocysteinemia may exert its pathogenic
effects largely through the metabolic accumulation of SAH, which
is a potent non-competitive inhibitor of COMT mediated
methylation of various catechol substrates, such as catecholamines
and catechol estrogens has been proposed [10]. In the case of
endogenous catecholamines in peripheral tissue, inhibition of their
methylation by SAH could theoretically result in elevation of
blood or tissue levels of catecholamines, and consequently, over-
stimulation of the cardiovascular system. The endogenous
catecholamines are also potentially reactive molecules. Our
findings from the KIHD Study are in line with recent hypothesis;
it seems that a moderate increase of serum tHcy (which may cause
a moderate inhibition of the COMT activity) may not reduce the
level of COMT activity below the minimally-required level in the
whole study population. However, in people already with
a compromised COMT activity, the pathogenic consequences
would be more readily detectable, and risk of acute coronary
events could increase.
The mean serum tHcy concentrations are rather similar to
other studies from Finland [21,22], a country where severe or
moderate hyperhomocysteinemia is relatively uncommon. The
negative tHcy-AMI findings in another Finnish study were
proposed to be due to the low prevalence of mutations
predisposing to hyperhomocysteinemia in the Finnish population
[22]. Indeed, homocystinuria is a hereditary disorder which is
extremely rare in Finland [23].
Our study is limited by the small number of outcome events,
reducing the power and preventing testing for interaction analyses
or including multiple covariates in the models. The major strength
of this study is its prospective population-based study design with
a long follow-up period.
In summary, although a high circulating level of tHcy does not
appear to predict acute coronary events in healthy men living in
eastern Finland, high tHcy could be a modest risk factor in
subpopulations with predisposing gene mutations, such as the
COMT low activity Met158Met genotype. Additional studies will
be required to provide more information about the COMT gene in
cardiovascular health.
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